Cardiovascular Chinese medicines

Cardiovascular and cerebrovascular market analysis of proprietary Chinese medicines

This is the medicine reported that the economy above article, henny1284 moderator in the chemical version of the drug, provided that my report and henny1284 provided by the moderator, you can learn about contrast.

Cardiovascular and cerebrovascular market analysis of proprietary Chinese medicines

Cardiovascular and cerebrovascular Chinese medicine refers to the treatment of coronary heart disease, stroke, myocardial infarction and the combined shock, arrhythmia, angina and hypertension and other cardiovascular and cerebrovascular diseases, Chinese medicines, including oral administration of Chinese medicine, Chinese medicine injections and other forms .

At present, cardiovascular and cerebrovascular diseases have become the health of residents of the most important disease in China each year about 260 million people a day, about 7,000 people die of cardiovascular disease.

With the prevalence of cardiovascular and cerebrovascular diseases, the increase in population, cardiovascular medicine has become the world's largest pharmaceutical market in drugs, according to IMS statistics, in 2003, cardiovascular drugs in the global pharmaceutical market in the first place, with a market share of 16.09 percent, the market size of 75,000,000,000 U.S. dollars. According to the SFDA in the South Medicine Economic Research Institute DCCC (Chinese drug consumption hierarchical model) estimated that in 2003, China's cardiovascular medicine at the Chinese pharmaceutical market ranks second only to anti-infective drugs, with a market share of 14.36 percent.

Cardiovascular and cerebrovascular diseases are more complicated mechanism, so as to molecular biology-based modern drug therapy in some areas is still difficult to effectively play the role of treatment. To this end, China's traditional Chinese medicine as a treatment for the disease in our cardiovascular drug on the market to occupy a very important position.

Great achievements of the big market brands

Market size is a measure of the market economy the most important characteristics of the target. According to the South Medicine Economic Research Institute estimated that CDCC model, in 2003, domestic cardiovascular Chinese medicines of the total retail market is about the size of 8,210,000,000 yuan (± 10%), accounting for about cardiovascular drugs (including proprietary Chinese medicines and chemical drugs) 25.41 percent of the overall market, China's pharmaceutical market, accounting for about 3.64 percent. 2003 Chinese medicines for cardiovascular marketing for the brand's largest Danshen pills, the goods in 2003 sales revenue of 819,000,000 yuan, the average retail market price, it is estimated that the total retail market size of about 1,087,000,000 yuan, the At present, Chinese goods is also the largest retail drug market brand. As a result of cardiovascular Chinese medicine market, therefore, not only extensive achievements China's largest retail drug market brands - Danshen pills, but also the achievement Tongxinluo, step Naoxintong, Di'aoxinxuekang, Jiuxin pill, Shu blood Ning, Mailuoning and ZJ, such as the size of the retail 500,000,000 yuan more than in the well-known brands.

Cardiovascular Chinese medicines belong to the more chronic drug use, the need for long-term use, consumers choose to buy the retail market for such drugs is a more convenient option, but the results show that the hospital is still the market of proprietary Chinese medicines, cardiovascular and cerebrovascular market-led, Accounted for 78.3 percent of the overall market, only to the retail market share of 21.7 percent. Hospital dominated the market because in elderly patients, especially elderly patients in the city for a doctor's compliance higher, is still the choice of hospital-based pharmaceutical.

Brand products scattered focus

According to statistical data, in 2003 cardiovascular Chinese medicines in 2002 year-on-year growth of 23.07 percent, the year 2004 is expected to grow 21.62 percent. From 1999-2003, cardiovascular and cerebrovascular Chinese medicine market, the average growth rate of about 23.75 percent. The last 5 years, Danshen pills, the average sales growth rate of 34.66 percent, compared with 22.99 percent Jiuxin pill, Tongxinluo for 45.56%, step size Xintong brain is about 19.20 percent, only Di'aoxinxuekang of the market Negative growth. From the main cardiocerebrovascular Chinese medicine brand growth, because of market demand (the overall size of) a faster growth rate, the main products are in a simultaneous increase in the growth stage, the product has not yet emerged between the radical alternative Competition.

2003 cardiovascular four major brands of proprietary Chinese medicines before the market's cumulative market share of 47.61 percent, from cardiovascular and cerebrovascular Chinese medicine market, the overall absolute concentration, cardiovascular and cerebrovascular market proprietary Chinese medicines currently distributed in more freedom and pro-competitive . That the overall market relatively decentralized reason that this was due to cardio-cerebral vascular function of Chinese medicine treatment of a larger scope (such as step Naoxintong capsules as defined in the "heart and brain Tongzhi," Tongxinluo capsule by relying on the "Network Theory of disease "), the product of direct competition extended to the level of cardiovascular medicine, leading to cardiovascular and cerebrovascular Chinese medicine market areas too; On the other hand, also reflects the proprietary Chinese medicines, cardiovascular and cerebrovascular absolutely no advantage Competitive difference. In the overall brand market concentration is more dispersed, in particular in the field of products, the proprietary Chinese medicines for cardiovascular market concentration is very high. Danshen in the film market, the former 4 products market share for a total of 73.5 percent, Baiyun Mountain in the pharmaceutical Danshen piece of market share as high as 43.83 percent; in the preparation of oral Ginkgo biloba market, the former 4 of a total product market share To 71.25 percent; inject liquid market in the ginkgo, the former total of 4 products as much as 91.45 percent market share. As a result, products from the competition area, the proprietary Chinese medicines for cardiovascular market is still focused on brand-led phase of the competition, the main market is still concentrated in the hands of a small number of brands.

Apparent differentiate competition

Competition in different markets, the competitiveness of existing enterprises in the form of a clear focus and the different antibiotics in the drug market, the price is competitive with the cost of the core brand and generic drugs market channel resources has become the biggest competitive advantage. Product differentiation is the cardiovascular market, the most important Chinese medicines core competitiveness. Cardiovascular and cerebrovascular of proprietary Chinese medicines, product differentiation is reflected in two aspects, one of differentiated products, including the form of differentiation (Danshen Danshen pills and tablets), the group's product differentiation; Second, The treatment of the theory of product differentiation, step size Xintong brain and strangulation Tongxinluo capsule is the most typical example of the theory of difference.

Especially in Hebei range of medicines, "Tong Capsule", the drug research and development to Professor Wu Yiling will be a traditional network TCM theory of disease and cardio-cerebral vascular diseases associated with the use of Chinese medicine network theory to explore coronary heart disease angina Chinese medicine and treatment of pathological mechanisms; and venae Stagnation and atherosclerosis, and coronary artery venae acute shortage cramps, heart disease and coronary heart disease network, the network of brain disease and stroke the relationship between the integrity of the organization into a modern version of "collateral disease Theory "by the treatment of the theory of differentiation, capsule-cerebro-vascular drugs market in mind and created a classic success story.